Dianthus Therapeutics raises $230M in PIPE financing at $12.00/share

Dianthus Therapeutics, Inc. /DE/

PIPE gross proceeds ~$230M from 14.5M common shares at $12.00 and 4.7M pre-funded warrants at $11.999.
New and existing investors participating: Bain Capital Life Sciences, RA Capital, Avidity Partners, and others.
Closing expected Jan 24, 2024; proceeds for R&D, working capital, and potential business development.
Placement agents: Jefferies, Evercore ISI, Stifel, Guggenheim Securities, Raymond James.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ entered into Registration Rights Agreement with Institutional and accredited investors valued at Registration Rights Agreement for resale registration (effective 2024-01-22).

Action: entry
Counterparty: Institutional and accredited investors
Value: Registration Rights Agreement for resale registration
Effective: 2024-01-22

Exact text from the filing

Also on January 22, 2024, the Company entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Purchasers, which provides that the Company will register the resale of the Common Shares and the Pre-Funded Warrant Shares.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Dianthus Therapeutics, Inc. /DE/ entered into Securities Purchase Agreement with Institutional and accredited investors valued at 230,000,000 USD (effective 2024-01-22).

Action: entry
Agreement: equity purchase
Counterparty: Institutional and accredited investors
Value: 230,000,000 USD
Effective: 2024-01-22

Exact text from the filing

On January 22, 2024, Dianthus Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") for a private placement (the "Private Placement") with certain institutional and accredited investors (each, a "Purchaser" and collectively, the "Purchasers").

View on SEC.gov

250 material agreements filed in the last 30 days. Browse all material agreements →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-24-011681

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.